Study: Marijuana Extract Associated With Improved Survival Rates In Glioma Patients
Brain tumor patients treated with marijuana extracts have increased survival rates compared to those who go untreated; this is according to newly released research.
Twenty-one patients with recurrent glioblastoma multiforme and who were undergoing conventional anti-cancer treatment participated in the study. Patients received either a proprietary cannabis extract containing a combination of THC and CBD or a placebo.
“[P]atients with documented recurrent GBM treated with THC:CBD had an 83 percent one year survival rate compared with 53 percent for patients in the placebo cohort,” the company summarized in a press release. “Median survival for the THC:CBD group was greater than 550 days compared with 369 days in the placebo group.”
The study’s findings replicate preclinical data demonstrating that the adjunctive use of cannabinoids with temozolomide may be associated with greater anti-cancer activity than the use of conventional therapy alone.
Glioblastoma multiforme is an especially aggressive form of cancer; only 28 percent of patients survive after one year and fewer than four percent surviving five years.